NVO:NYSE
Novo Nordisk A/S
43,19 $
arrow_upward
+3,52%(+1,47) 1 d.
43,33 $
arrow_upward
+0,32% (+0,14)bedtimePēctirdzniecības
Slēgts: 17. sept., 16:03:54 GMT-4 · USD
search
Visi simboli
1 d.
5 d.
1 m.
6 m.
Š.g.
1 g.
5 g.
Maks.
| Simbols | Cena | Izmaiņas | % izmaiņu |
|---|
insights_autoNotiek galveno ieskatu ģenerēšana par šādu tēmu: NVO…
Atvērt
41,98 $
Augsta
43,44 $
Zema
41,96 $
Tirgus kapitalizācija
147,79 mljrd.
Vid. apjoms
10,93 milj.
Apjoms
12,93 milj.
Dividende
4,16%
Ceturkšņa dividendes
0,45 $
Datums, kad tiek pārtraukta dividenžu izmaksa
2026. gada 14. aug.
Cenas/peļņas attiecība
10,76
Augstākā 52 ned.
64,16 $
Zemākā 52 ned.
35,12 $
Peļņa uz vienu akciju
4,02 $
Beta
0,73
Apgrozībā esošās akcijas
3,39 mljrd.
Darbinieku skaits
67 tūkst.
Atvērt
41,98 $
Augsta
43,44 $
Zema
41,96 $
Tirgus kapitalizācija
147,79 mljrd.
Vid. apjoms
10,93 milj.
Apjoms
12,93 milj.
Dividende
4,16%
Ceturkšņa dividendes
0,45 $
Datums, kad tiek pārtraukta dividenžu izmaksa
2026. gada 14. aug.
Cenas/peļņas attiecība
10,76
Augstākā 52 ned.
64,16 $
Zemākā 52 ned.
35,12 $
Peļņa uz vienu akciju
4,02 $
Beta
0,73
Apgrozībā esošās akcijas
3,39 mljrd.
Darbinieku skaits
67 tūkst.
Ziņas un raksti
No tīmekļa avotiem un ziņu partneriem
GuruFocus
·
pirms 1 stundas
Is It Too Late to Buy Novo Nordisk AS (NVO) After 3.5% Rally? GF Value Says Undervalued
Yahoo Finance
·
pirms 4 stundām
NVO Stock Jumps 4% As European Committee Backs Novo’s Haemophilia Pen
Benzinga
·
pirms 6 stundām
EMA Committee Endorses Novo Nordisk's Hemophilia A Therapy
Stock Titan
·
pirms 6 stundām
EU backs new haemophilia A shot from Novo Nordisk (NYSE: NVO)
Profils
Novo is a Danish multinational pharmaceutical company headquartered in Bagsværd. Novo is controlled by majority shareholder Novo Holdings A/S which holds approximately 28.1% of its shares and a majority of its voting shares.
Novo manufactures and markets pharmaceutical products and services, primarily diabetes and obesity medications and devices.
Novo employs more than 48,000 people globally, and markets its products in 168 countries. The corporation was created in 1989, through a merger of two Danish companies, which date back to the 1920s. Novo is a full member of the European Federation of Pharmaceutical Industries and Associations.
The company was ranked 25th among Fortune's 100 Best Companies to Work For in 2010, and subsequently ranked 72nd in 2014 and 73rd in 2017. In January 2012, Novo was named the most sustainable company in the world by the business magazine Corporate Knights, while spin-off company Novozymes was named fourth. It is a leader in the FTSE4Good Index, and the only European company in the top ten. Novo is the largest pharmaceutical company in Denmark. Wikipedia
Par “Novo Nordisk A/S”
ĢenerāldirektorsMaziar Mike Doustdar
Darbinieki66,7 tūkst.
Dibināšanas datums1923. gada 21. dec.
Galvenais birojsBagsværd, Galvaspilsētas reģions, Dānija
Sektors-
Tīmekļa vietnenovonordisk.com